Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00694655 · ClinicalTrials.gov registry record · Phase 4
Human Immune Responses to Yellow Fever Vaccination
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 239
- Enrollment target
NCT00694655 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 239 participants.
The verdict
NCT00694655, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 239 participants
- Enrollment target
Study Summary
The goal of this study is to use the live attenuated Yellow Fever Vaccine (YFV) as a safe and effective model for viral infection to understand human immune response to viral antigens. Study participants will receive the yellow fever vaccine and participation in the study may be as short as one month or as long as one year, depending on immune responses.
Interventions
- PROCEDURE Leukapheresis
- BIOLOGICAL Yellow Fever Vaccine
- PROCEDURE Fine-needle aspiration (FNA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2008-05 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00694655
The ClinicalTrials.gov registry entry for NCT00694655 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Leukapheresis is the first listed.
NCT00694655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00694655 about?
NCT00694655 is a clinical study titled "Human Immune Responses to Yellow Fever Vaccination". The goal of this study is to use the live attenuated Yellow Fever Vaccine (YFV) as a safe and effective model for viral infection to understand human immune response to viral antigens. Study participants will receive the yellow fever vaccine and participation in the study may be as short as one mont...
What is the current status of trial NCT00694655?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 239 participants. The study started on 2008-05. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT00694655?
The interventions under investigation include: Leukapheresis (PROCEDURE), Yellow Fever Vaccine (BIOLOGICAL), Fine-needle aspiration (FNA) (PROCEDURE).
Who is sponsoring clinical trial NCT00694655?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.